- Home
- LIXT vs CYCN Comparison
LIXT vs CYCN Comparison
Compare LIXT & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- CYCN
- Stock Information
- Founded
- LIXT 2005
- CYCN 2018
- Country
- LIXT United States
- CYCN United States
- Employees
- LIXT N/A
- CYCN N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- LIXT Health Care
- CYCN Health Care
- Exchange
- LIXT Nasdaq
- CYCN Nasdaq
- Market Cap
- LIXT 12.4M
- CYCN 11.8M
- IPO Year
- LIXT N/A
- CYCN N/A
- Fundamental
- Price
- LIXT $4.85
- CYCN $2.40
- Analyst Decision
- LIXT
- CYCN
- Analyst Count
- LIXT 0
- CYCN 0
- Target Price
- LIXT N/A
- CYCN N/A
- AVG Volume (30 Days)
- LIXT 193.9K
- CYCN 58.4K
- Earning Date
- LIXT 08-07-2025
- CYCN 08-05-2025
- Dividend Yield
- LIXT N/A
- CYCN N/A
- EPS Growth
- LIXT N/A
- CYCN N/A
- EPS
- LIXT N/A
- CYCN N/A
- Revenue
- LIXT N/A
- CYCN $2,174,000.00
- Revenue This Year
- LIXT N/A
- CYCN N/A
- Revenue Next Year
- LIXT N/A
- CYCN N/A
- P/E Ratio
- LIXT N/A
- CYCN N/A
- Revenue Growth
- LIXT N/A
- CYCN N/A
- 52 Week Low
- LIXT $0.64
- CYCN $1.27
- 52 Week High
- LIXT $5.14
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- LIXT 64.92
- CYCN 40.00
- Support Level
- LIXT $4.20
- CYCN $2.10
- Resistance Level
- LIXT $5.06
- CYCN $2.41
- Average True Range (ATR)
- LIXT 0.44
- CYCN 0.25
- MACD
- LIXT -0.02
- CYCN -0.06
- Stochastic Oscillator
- LIXT 80.79
- CYCN 28.85
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.